志道國際(01220.HK):目前共參與6份建築合約涉8.94億元 股份續停牌
志道國際(01220.HK)公布最新業務營運消息,指儘管股份暫停買賣,集團仍繼續進行業務營運。為證明其符合上市規則第13.24條規定,集團持續發展其於香港及澳門之建築業務。
目前,集團共參與3份香港建築合約及3份澳門建築合約,合約金額分別為9,670萬元及7.97億元。自股份暫停買賣以來,集團不斷尋求新項目機會,並準備競投2個新香港項目。
在項目中,所有項目將以旗下附屬公司之名義競投。集團亦積極擴大其建築業務團隊,團隊人數由2019年3月31日之9名增至目前的70名。
另外,公司股份將繼續於聯交所暫停買賣,以待達成復牌指引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.